drugset / Trial / NCT01467687

Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions

NCT01467687

Phase 1 Completed 58 enrolled Synerx Pharma, LLC
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to determine the bioequivalency of Synerx Pharma Verapamil extended release capsules.

Timeline

Start
2007-07
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Verapamil Other / unclassified 300 mg Oral

Indications

No indication recorded.